Newark, New Castle, USA, March 21, 2023 (GLOBE NEWSWIRE) — The global human babesiosis treatment market is anticipated to reach US$ 1,199 million by 2030; the high incidence of babesiosis coupled with increasing research and development are primary factors supporting the global human babesiosis treatment market, States Growth Plus Reports.
The global human babesiosis treatment market is driven by the rising prevalence of the disease, increasing awareness about the disease, rising pharmaceutical investments, and an upsurge in research and development activities. The prevalence of babesiosis has been increasing in recent years due to the rise in vector-borne diseases and increasing transmission of the disease through ticks. Additionally, governments and non-governmental organizations (NGOs) initiatives to increase awareness about the disease are projected to drive the human babesiosis treatment market. Moreover, the increasing investment by pharmaceutical companies in developing novel drugs for the treatment of babesiosis is projected to fuel the growth of the global human babesiosis treatment market in the forecast years.
The global human babesiosis treatment market has been analyzed from four perspectives: Drug Class, Mode of Administration, Distribution Channel, and Region.
Request a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/human-babesiosis-treatment-market/8193
Human Babesiosis Treatment Market Scope
| Report Attribute | Details |
| Market size value in 2021 | US$ 780.1 million |
| Revenue Forecast in 2030 | US$ 1199 million |
| Growth Rate | CAGR of 4.9% from 2022 to 2030 |
| Base year for estimation | 2021 |
| Forecast Period | 2022-2030 |
| Historical Year | 2020 |
| Segments Covered | Drug Class, Mode of Administration, Distribution Channel, and Region |
| Regional Scope | North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
Excerpts from ‘By Drug Class
Based on drug class the global human babesiosis treatment market according to drug class is bifurcated into:
- Antiparasitic
- Antibiotics
The antiparasitic segment holds the majority of the market share. This is owing to the antiparasitic drug’s efficacy, which reduces the disease’s symptoms. The antiparasitic drug segment is again sub-segmented into atovaquone and quinine. Atovaquone has dominated the segment. Over the years, atovaquone has shown effective results in treating babesiosis. Moreover, due to the drug’s high efficacy in combination with antibiotics such as azithromycin, it is given in the first-line treatment of babesiosis. Atovaquone has many advantages over other treatments, such as its long-acting, fast-acting, and broad-spectrum effects. The antibiotics segment is expected to show high growth in the coming years.
The antibiotics segment is again classified into azithromycin and clindamycin. Among these, azithromycin is highly demanding. For several years, azithromycin has been the preferred antibiotic in treating babesiosis. This drug is highly effective in a wide range of Babesia species. It is effective at treating both acute and chronic infections and is especially useful for cases that are unresponsive to other treatments.
Excerpts from ‘By Mode of Administration’
The global human babesiosis treatment market is divided into two segments based on the mode of administration:
- Parenteral
- Oral
The oral segment holds the majority of market shares. This is because most medications prescribed to treat babesiosis are available in oral form. Furthermore, oral treatments are simple to use and act fast to relieve symptoms of babesiosis. Additionally, oral drugs have fewer side effects than other kinds of therapy, like intravenous antibiotics.
Excerpts from ‘By Distribution Channel’
Based on distribution channels, the global human babesiosis treatment market is segmented into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Hospital pharmacy has dominated the market. The hospital pharmacy segment is experiencing growth due to the increasing demand for medications and their need for proper distribution. Hospital pharmacies can provide a more efficient, cost-effective, and convenient way to dispense medications. In addition, hospital pharmacy’s specialized awareness, quality assurance, and safety standards provide an additional benefit to patients.
Excerpts from ‘By Region’
The global human babesiosis treatment market regionally is divided into:
- North America
- Europe
- Asia Pacific
- Rest of The World
In 2021, North America held the largest market share. The increasing human babesiosis treatment market in North America is primarily driven by the growth of the region’s population, as the demand for medical care increases. Additionally, the region has seen a rise in the number of medical tourists seeking babesiosis treatments in the area. This trend is further encouraged by the availability of specialized treatments, such as those offered by the Babesia Research Institute. Finally, the region’s governments are investing in modernizing the healthcare infrastructure to make care more accessible, driving the growth of the human babesiosis treatment market.
The market for babesiosis treatment in the Asia Pacific region is expected to grow in the coming years due to several factors. One of the primary drivers of the market is the increasing prevalence of the disease in the region. The presence of vector-borne agents aids the spread of babesiosis. Additionally, the growing awareness regarding the importance of the disease and the need for timely diagnosis and treatment is expected to boost market growth. The rising healthcare expenditure in the region is also projected to support market growth in the forecast years.
Request for Customization – https://www.growthplusreports.com/inquiry/customization/human-babesiosis-treatment-market/8193
Excerpts from ‘Competitive Landscape
Some of the prominent players operating in the global human babesiosis treatment market are:
- GlaxoSmithKline plc
- Sun Pharmaceuticsl Industries Ltd.
- Pliva d.o.o (Teva Pharmaceutical)
- Pfizer, Inc.
- Camber Pharmaceuticals, Inc.
- Galderma S.A.
- Abbott Laboratories
- Mylan pharmaceutical inc.
- Epic Pharma LLC
- Otto Pharmaceutical Industries.
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years – 2020
- Base Year – 2021
- Forecast Years – 2022 to 2030
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trends
- Key Players & Competitive Positioning (2021)
- MARKET DYNAMICS
- Drivers
- Restraints/Challenges
- Opportunities
- GLOBAL HUMAN BABESIOSIS TREATMENT MARKET – ANALYSIS & FORECAST, BY DRUG CLASS
- Antiparasitic Drugs
- Atovaquone
- Quinine
- Antibiotics
- Azithromycin
- Clindamycin
- Antiparasitic Drugs
- GLOBAL HUMAN BABESIOSIS TREATMENT MARKET – ANALYSIS & FORECAST, BY MODE OF ADMINISTRATION
- Oral
- Intravenous
- GLOBAL HUMAN BABESIOSIS TREATMENT MARKET – ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
TOC Continued..
Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8193
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- ‘Business Profile’ of Key Players
Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction
Visit our report store at – https://www.growthplusreports.com/report-store
Browse related reports:
Continuing Medical Education Market by Provider (Universities and Academic Centers), Delivery Mode (Classroom Based Courses, E-Learning Solutions), Application (Oncology, Cardiology) – Global Outlook & Forecast 2023-2031
Clostridium Difficile Infections Treatment Market by Drug (Metronidazole, Vancomycin), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook and Forecast 2023-2031
Bioprocess Technology Market by Product Type (Cell Culture, Flow Cytometry), Application (Biopharmaceuticals, Environmental Management Aid), End User (Hospitals, CROs & CMOs) – Global Outlook & Forecast 2023-2031
Automated Breast Ultrasound Systems Market by Product (Automated Breast Ultrasound System, Automated Breast Volume Scanner), End User (Hospitals, Diagnostics Imaging Laboratories, Clinics) – Global Outlook & Forecast 2023-2031
Attention Deficit Hyperactivity Disorder Market by Drug Class (Stimulant, Non-stimulant), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Outlook and Forecast 2023-2031
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.
CONTACT: Manan Sethi Director, Market Insights Email: sales@growthplusreports.com 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web: https://www.growthplusreports.com/